Aurobindo Pharma Q3 net marginally down at Rs 705 cr, revenue up 12%

Formulation revenue for the quarter posted a growth of 17.4 per cent YoY to Rs 5,104.9 crore and accounted for 86.6 per cent of total revenues.
Aurobindo Pharma on Thursday said its net profit for the quarter ended December 31, 2019 was marginally down by one per cent to Rs 705.3 crore against Rs 712.2 crore during the corresponding period last fiscal.

According to a filing with the bourses, revenues from operations during the quarter under review was up by nearly 12 per cent to Rs 5,895 crore. It was Rs 5,269.7 crore in Q3 FY19.

Commenting on the performance, N Govindarajan, Managing Director of the company said: "We continue to perform well across all our key geographies. We remain focused on strengthening our existing businesses and developing a differentiated and specialty driven product portfolio. We are committed to resolve all pending regulatory issues and continuously improve quality."

Formulation revenue for the quarter posted a growth of 17.4 per cent YoY to Rs 5,104.9 crore and accounted for 86.6 per cent of total revenues.

US formulations revenue registered 22 per cent growth at Rs 2,969.4 crore against Rs 2,433.2 in the third quarter of FY19 while Europe formulations revenue was at Rs 1,476.3 crorean increase of 14.2 per cent against Q3FY19.

The Board of Directors of the company at its meeting held on Thursday approved a second interim dividend of Rs 1. 75 per equity share of Re.1 each on the equity share capital of the company for the financial year 2019-20.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel